Karo Pharma AB (Karo Pharma AB) Total Liabilities : $1,020.0 Mil (As of Jun. 2022)

View and export this data going back to . Start your Free Trial

What is Karo Pharma AB Total Liabilities?

Karo Pharma AB's Total Liabilities for the quarter that ended in Jun. 2022 was $1,020.0 Mil.

Karo Pharma AB's quarterly Total Liabilities declined from Sep. 2021 ($813.99 Mil) to Dec. 2021 ($745.81 Mil) but then increased from Dec. 2021 ($745.81 Mil) to Jun. 2022 ($1,019.98 Mil).

Karo Pharma AB's annual Total Liabilities increased from Dec. 2019 ($557.29 Mil) to Dec. 2020 ($822.54 Mil) but then declined from Dec. 2020 ($822.54 Mil) to Dec. 2021 ($745.81 Mil).

Karo Pharma AB Total Liabilities Historical Data

The historical data trend for Karo Pharma AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB Total Liabilities Chart

Karo Pharma AB Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Liabilities

Get a 7-Day Free Trial

304.48

362.52

557.29

822.54

745.81

Karo Pharma AB Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Jun22
Total Liabilities	Get a 7-Day Free Trial															808.00	878.45	813.99	745.81	1,019.98

Karo Pharma AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Karo Pharma AB's Total Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	64.507	+	(619.671	+	61.63
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	745.8

Total Liabilities	=	Total Assets (A: Dec. 2021 )	-	Total Equity (A: Dec. 2021 )
	=	1385.475	-	639.667
	=	745.8

Karo Pharma AB's Total Liabilities for the quarter that ended in Jun. 2022 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	62.382	+	(859.57	+	98.028
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,020.0

Total Liabilities	=	Total Assets (Q: Jun. 2022 )	-	Total Equity (Q: Jun. 2022 )
	=	1842.848	-	822.868
	=	1,020.0

Karo Pharma AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Karo Pharma AB (Karo Pharma AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OTCPK:KARBF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22

Website

https://www.karopharma.com

Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.

Karo Pharma AB (Karo Pharma AB) Headlines

From GuruFocus

Avista Capital Partners To Sell Trimb To Karo Pharma

By PRNewswire PRNewswire • 06-25-2019